Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALML3 | P27482 | 7/20 | 0.59 |
| ▸ | MAOB | P27338 | 10/20 | 0.58 |
| ▸ | MAOA | P21397 | 5/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.58 |
| ▸ | SDHA | P31040 | 1/20 | 0.58 |
| ▸ | F10 | P00742 | 3/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3575563 | 1.00 | CALML3 (0.59) | CALML3MAOBMAOALMNAPTGS1 | |
| SCHEMBL28109794 | 0.91 | CALML3 (0.65) | CALML3MAOBMAOALMNAPTGS1 | |
| SCHEMBL28109791 | 0.89 | CALML3 (0.64) | CALML3MAOBMAOALMNAPTGS1 | |
| SCHEMBL16204405 | 0.89 | CALML3 (0.64) | CALML3MAOBMAOALMNAPTGS1 | |
| SCHEMBL2829206 | 0.88 | MAOB (0.72) | CALML3MAOBMAOALMNAPTGS1 | |
| SCHEMBL3197103 | 0.88 | F10 (0.65) | CALML3MAOBMAOALMNAPTGS1 | |
| SCHEMBL15793246 | 0.88 | MAOB (0.72) | CALML3MAOBMAOALMNAPTGS1 | |
| SCHEMBL6629866 | 0.88 | F10 (0.65) | CALML3MAOBMAOALMNAPTGS1 | |
| SCHEMBL2829207 | 0.88 | MAOB (0.72) | CALML3MAOBMAOALMNAPTGS1 | |
| SCHEMBL29822424 | 0.88 | MAOB (0.72) | CALML3MAOBMAOALMNAPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8729269-B2 | Substituted piperidino phenyloxazolidinones having antimicrobial activity with improved in vivo efficacy | WOCKHARDT LIMITED (IN) | 2014-05-20 | — | — | US | disclosed |
| US-8729269-B2 | Substituted piperidino phenyloxazolidinones having antimicrobial activity with improved in vivo efficacy | WOCKHARDT LIMITED (IN) | 2014-05-20 | — | — | US | disclosed |
| US-8729269-B2 | Substituted piperidino phenyloxazolidinones having antimicrobial activity with improved in vivo efficacy | WOCKHARDT LIMITED (IN) | 2014-05-20 | — | — | US | disclosed |
| US-20100144735-A1 | SUBSTITUTED PIPERIDINO PHENYLOXAZOLIDINONES HAVING ANTIMICROBIAL ACTIVITY WITH IMPROVED IN VIVO EFFICACY | WOCKHARDT LIMITED | 2010-06-10 | — | — | US | disclosed |
| US-20100144735-A1 | SUBSTITUTED PIPERIDINO PHENYLOXAZOLIDINONES HAVING ANTIMICROBIAL ACTIVITY WITH IMPROVED IN VIVO EFFICACY | WOCKHARDT LIMITED | 2010-06-10 | — | — | US | disclosed |
| US-20100144735-A1 | SUBSTITUTED PIPERIDINO PHENYLOXAZOLIDINONES HAVING ANTIMICROBIAL ACTIVITY WITH IMPROVED IN VIVO EFFICACY | WOCKHARDT LIMITED | 2010-06-10 | — | — | US | disclosed |
| US-7687627-B2 | Substituted piperidino phenyloxazolidinones having antimicrobial activity with improved in vivo efficacy | WOCKHARDT LIMITED (IN) | 2010-03-30 | — | — | US | disclosed |
| US-7687627-B2 | Substituted piperidino phenyloxazolidinones having antimicrobial activity with improved in vivo efficacy | WOCKHARDT LIMITED (IN) | 2010-03-30 | — | — | US | disclosed |
| US-7687627-B2 | Substituted piperidino phenyloxazolidinones having antimicrobial activity with improved in vivo efficacy | WOCKHARDT LIMITED (IN) | 2010-03-30 | — | — | US | disclosed |
| US-7405228-B2 | Antibacterial cyano-(substituted)-methylenepiperidinophenyl oxazolidinones targeting multiple ribonucleoprotein sites | WOCKHARDT LIMITED (IN) | 2008-07-29 | — | — | US | disclosed |
| EP-1664038-A2 | SUBSTITUTED PIPERIDINO PHENYLOXAZOLIDINONES HAVING ANTIMICRIOBIAL ACTIVITY WITH IMPROVED I IN VIVO /I EFFICACY | Wockhardt Limited (IN) | 2006-06-07 | — | — | EP | disclosed |
| EP-1565461-A2 | ANTIBACTERIAL SUBSTITUTED CYANOMETHYL(ENE)PIPERIDINOPHENYL OXAZOLIDINONES, PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Patel, Mahesh V. (IN) | 2005-08-24 | — | — | EP | disclosed |
| US-20050143421-A1 | Substituted piperidino phenyloxazolidinones having antimicrobial activity with improved in vivo efficacy | WOCKHARDT LIMITED | 2005-06-30 | — | — | US | disclosed |
| WO-2005054234-A2 | SUBSTITUTED PIPERIDINO PHENYLOXAZOLIDINONES HAVING ANTIMICRIOBIAL ACTIVITY WITH IMPROVED IN VIVO EFFICACY | WOCKHARDT LIMITED (IN) | 2005-06-16 | — | — | WO | disclosed |
| US-20040063954-A1 | Antibacterial cyano-(substituted)-methylenepiperidinophenyl oxazolidinones targeting multiple ribonucleoprotein sites | WOCKHARDT LIMITED | 2004-04-01 | — | — | US | disclosed |
| WO-2004007489-A2 | ANTIBACTERIAL SUBSTITUTED CYANOMETHYL (ENE) PIPERIDINOPHENYL OXAZOLIDINONES, PROCESS OR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | WOCKHARDT LIMITED (IN) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144735-A1 | SUBSTITUTED PIPERIDINO PHENYLOXAZOLIDINONES HAVING ANTIMICROBIAL ACTIVITY WITH IMPROVED IN VIVO EFFICACY | GMPS, MPO, ARG1 | CALML3 3882/4885MAOB 2975/4885MAOA 2638/4885 |
| US-20050143421-A1 | Substituted piperidino phenyloxazolidinones having antimicrobial activity with improved in vivo efficacy | GMPS, MPO, ARG1 | CALML3 3882/4885MAOB 2975/4885MAOA 2638/4885 |
| US-20040063954-A1 | Antibacterial cyano-(substituted)-methylenepiperidinophenyl oxazolidinones targeting multiple ribonucleoprotein sites | POLRMT, RNASEL, RNASE1 | CALML3 3773/4885MAOB 2080/4885MAOA 1873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.